About Stemline Therapeutics
Stemline Therapeutics is a company based in New York (United States) founded in 2003 by Ivan Bergstein was acquired by Menarini in May 2020. It operates as a Direct-to-Consumer (D2C). Stemline Therapeutics has raised $15.09 million across 4 funding rounds from investors including Pequot Capital Management and Menarini Group. The company has 131 employees as of December 31, 2022. Stemline Therapeutics has completed 1 acquisition, including Primrose Therapeutics. Stemline Therapeutics offers products and services including ELZONRIS and ORSERDU. Stemline Therapeutics operates in a competitive market with competitors including Adicet Bio, ImmunoACT, Orca Bio, Ossium Health and Nordic Nanovector, among others.
- Headquarter New York, United States
- Employees 131 as on 31 Dec, 2022
- Founders Ivan Bergstein
- Stage Public
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Stemline Therapeutics, Inc.
-
Annual Revenue
$898.2 K0as on Dec 31, 2017
-
Net Profit
$-76.82 M10as on Dec 31, 2019
-
EBITDA
$-79.25 M8as on Dec 31, 2019
-
Total Equity Funding
$15.09 M (USD)
in 4 rounds
-
Latest Funding Round
$740 K (USD), Series A
Jan 17, 2012
-
Investors
Pequot Capital Management
& 1 more
-
Employee Count
131
as on Dec 31, 2022
- Investments & Acquisitions
-
Acquired by
Menarini
(May 04, 2020)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Stemline Therapeutics
Stemline Therapeutics offers a comprehensive portfolio of products and services, including ELZONRIS and ORSERDU. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Used for treating blastic plasmacytoid dendritic cell neoplasm.
Indicated for ER-positive, HER2-negative advanced breast cancer.
Unlock access to complete
Leadership Team
51 people
Software Development Team
32 people
Sales and Marketing
22 people
Medical Team
12 people
Senior Team
9 people
Operations Team
9 people
Legal and Compliance
8 people
Product Management Team
5 people
Unlock access to complete
Funding Insights of Stemline Therapeutics
Stemline Therapeutics has successfully raised a total of $15.09M across 4 strategic funding rounds. The most recent funding activity was a Series A round of $740 thousand completed in January 2012. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 4
- Last Round Series A — $740,000
-
First Round
First Round
(09 Apr 2008)
- Investors Count 1
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jan, 2012 | Amount | Series A - Stemline Therapeutics | Valuation |
investors |
|
| Apr, 2010 | Amount | Series A - Stemline Therapeutics | Valuation |
investors |
|
| Mar, 2010 | Amount | Series A - Stemline Therapeutics | Valuation |
investors |
|
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Stemline Therapeutics
Stemline Therapeutics has secured backing from 2 investors, including institutional investors. Prominent investors backing the company include Pequot Capital Management and Menarini Group. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
-
|
Founded Year | Domain | Location | |
|
Menarini Group is engaged in pharmaceutical and healthcare solutions.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Stemline Therapeutics
Stemline Therapeutics has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Primrose Therapeutics. These strategic investments and acquisitions demonstrate the company's commitment to growth through portfolio expansion, market consolidation, technology integration, and strategic partnerships that enhance competitive positioning and drive long-term value creation.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Biotechnology company focused on the development of treatments for Polycystic Kidney Disease (PKD)
|
2010 |
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
OVO is recognized as a smart digital payment application.
|
2017 | ||||
|
Bionic investment advisor platform
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 |
Financial Statements - Stemline Therapeutics
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Stemline Therapeutics Comparisons
Competitors of Stemline Therapeutics
Stemline Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Adicet Bio, ImmunoACT, Orca Bio, Ossium Health and Nordic Nanovector, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Immune cell therapies for cancer treatment are developed.
|
|
| domain | founded_year | HQ Location |
Cell therapies for cancer treatment are developed.
|
|
| domain | founded_year | HQ Location |
Developer of Allogeneic cell therapy for cancer, autoimmune diseases and genetic blood disorders
|
|
| domain | founded_year | HQ Location |
Ossium Health is focused on bioengineering for improved health.
|
|
| domain | founded_year | HQ Location |
Antibody radionuclide conjugates are developed for haematological cancers.
|
|
| domain | founded_year | HQ Location |
Therapeutic solutions for hematopoietic stem cell transplants are developed.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Stemline Therapeutics
Frequently Asked Questions about Stemline Therapeutics
When was Stemline Therapeutics founded?
Stemline Therapeutics was founded in 2003 and raised its 1st funding round 5 years after it was founded.
Where is Stemline Therapeutics located?
Stemline Therapeutics is headquartered in New York, United States. It is registered at New York, New York, United States.
Who is the current CEO of Stemline Therapeutics?
Ivan Bergstein is the current CEO of Stemline Therapeutics. They have also founded this company.
Is Stemline Therapeutics a funded company?
Stemline Therapeutics is a funded company, having raised a total of $15.09M across 4 funding rounds to date. The company's 1st funding round was a Series A of $1.25M, raised on Apr 09, 2008.
How many employees does Stemline Therapeutics have?
As of Dec 31, 2022, the latest employee count at Stemline Therapeutics is 131.
What is the annual revenue of Stemline Therapeutics?
Annual revenue of Stemline Therapeutics is $898.2K as on Dec 31, 2017.
What does Stemline Therapeutics do?
Stemline Therapeutics, part of the Menarini Group, is dedicated to the development of innovative therapies in oncology. The company focuses on transforming the lives of cancer patients through a broad pipeline of transformative treatments. Their key products include ELZONRIS for blastic plasmacytoid dendritic cell neoplasm and ORSERDU for advanced breast cancer. Operations are centered in therapeutic areas with high unmet needs, contributing to advancements in cancer care.
Who are the top competitors of Stemline Therapeutics?
Stemline Therapeutics's top competitors include Orca Bio, Ossium Health and Adicet Bio.
What products or services does Stemline Therapeutics offer?
Stemline Therapeutics offers ELZONRIS and ORSERDU.
How many acquisitions has Stemline Therapeutics made?
Stemline Therapeutics has made 1 acquisition, including Primrose Therapeutics.
Who are Stemline Therapeutics's investors?
Stemline Therapeutics has 2 investors. Key investors include Pequot Capital Management, and Menarini Group.
Book a demo & talk to our team
Share a few details and we’ll reach out to schedule a session.